文献速递糖尿病

2型糖尿病精准医疗:靶向SGLT2抑制剂治疗以保护肾脏

Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection.
PubMed 文献 · Diabetologia · 2025-11-09

本研究利用英国初级保健电子健康记录数据,开发并验证了一个预测模型,用于估算2型糖尿病且无或早期慢性肾脏病患者使用SGLT2抑制剂的个体化肾脏保护绝对获益。模型基于CKD-PC风险评分整合相对治疗效果,预测3年绝对风险降低,校准良好,且比基于尿白蛋白/肌酐比值≥3 mg/mmol的阈值策略更有效。

要点

  • SGLT2抑制剂较DPP4抑制剂/磺脲类药物降低肾脏病进展相对风险42%(HR 0.58)。
  • 模型预测的3年绝对风险降低中位数为0.37%,校准斜率1.10。
  • 模型指导的治疗策略比白蛋白尿阈值策略在3年内预防超过10%的事件。

核心结论

  • 模型能准确预测2型糖尿病无或早期CKD患者使用SGLT2抑制剂的个体化肾脏保护获益。
  • 模型指导的治疗策略可能比当前指南推荐的uACR≥3 mg/mmol阈值更有效。

研究设计与样本

  • 观察性队列研究,使用英国初级保健电子健康记录(Clinical Practice Research Datalink,2013-2020)。
  • 纳入53,096例SGLT2抑制剂起始者和88,404例DPP4抑制剂/磺脲类药物起始者。
  • 纳入标准:成人2型糖尿病,eGFR≥60 ml/min per 1.73 m2,uACR<30 mg/mmol,无心力衰竭或动脉粥样硬化性血管疾病。

主要发现

  • SGLT2抑制剂与肾脏病进展相对风险降低42%相关(HR 0.58;95% CI 0.48, 0.69)。
  • CKD-PC风险评分无需重新校准(校准斜率1.05;95% CI 0.94, 1.17)。
  • 模型预测的3年绝对风险降低中位数为0.37%(IQR 0.26-0.55),校准良好(斜率1.10;95% CI 1.09, 1.12)。
  • 模型指导策略 targeting 17.9%人群(n=25,303)可预防253例事件,而白蛋白尿阈值策略预防228例。
  • 在uACR<3 mg/mmol的个体中,有6.7%亚组显示显著更大的绝对风险降低(5年扩展观察分析:3.2% vs 1.2%,p=0.05)。

关键数值与推荐

  • 当前指南推荐uACR≥3 mg/mmol的2型糖尿病早期CKD患者使用SGLT2抑制剂进行肾脏保护。
  • 模型预测的3年绝对风险降低中位数为0.37%,可用于个体化治疗决策。

临床怎么用

  • 模型可辅助临床医生识别从SGLT2抑制剂肾脏保护中获益更大的个体,超越单一白蛋白尿阈值。
  • 对于uACR<3 mg/mmol的患者,模型可识别绝对获益显著亚组,指导治疗强化。

局限性

  • 研究为观察性设计,可能存在未测量混杂。
  • 模型验证基于英国初级保健数据,外推性需进一步评估。
  • uACR<3 mg/mmol亚组的5年分析结果p=0.05,处于统计学边缘。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. However, individuals with a normal uACR or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about absolute treatment benefit in this group. To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through the use of SGLT2 inhibitors. METHODS: This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m2 and uACR <30 mg/mmol, without heart failure or atherosclerotic vascular disease, who were starting treatment with either SGLT2 inhibitors or the comparator drugs dipeptidyl peptidase-4 (DPP4) inhibitors/sulfonylureas. First, we confirmed the real-world applicability of the relative treatment effect from a previous SGLT2 inhibitor trial meta-analysis, using overlap-weighted Cox proportional hazards models. Second, we assessed calibration of the CKD-PC risk score for kidney disease progression (≥50% eGFR decline, end-stage kidney disease or kidney-related death). Third, we integrated the relative treatment effect with the risk score to predict 3 year individual-level absolute risk reductions for SGLT2 inhibitors, and validated the accuracy of predictions vs overlap-weighted estimates based on observed data. Finally, we compared the clinical utility of a model-based treatment strategy with that of the ≥3 mg/mmol albuminuria threshold. RESULTS: In 53,096 initiations of SGLT2 inhibitor treatment compared with 88,404 initiations of DPP4 inhibitor/sulfonylurea treatment, there was a 42% lower relative risk of kidney disease progression with SGLT2 inhibitors (HR 0.58; 95% CI 0.48, 0.69), consistent with a previous trial meta-analysis. The CKD-PC risk score did not require recalibration (calibration slope 1.05; 95% CI 0.94, 1.17). The median overall model-predicted absolute risk reduction with SGLT2 inhibitors was 0.37% at 3 years (IQR 0.26-0.55), and showed good calibration (calibration slope 1.10; 95% CI 1.09, 1.12). As an illustration of clinical utility, using the model predictions to target the same proportion of the population (n=25,303, 17.9%) as the albuminuria threshold would prevent over 10% more events over 3 years (253 vs 228) by identifying a subgroup of 6.7% of individuals with uACR <3 mg/mmol who showed significantly greater absolute risk reduction in response to SGLT2 inhibitor treatment than the remainder with uACR <3 mg/mmol (3.2% vs 1.2% in extended 5 year observational analyses, p=0.05). CONCLUSIONS/INTERPRETATION: A model adapting the international CKD-PC risk score can accurately predict the individual-level kidney protection benefit from treatment with SGLT2 inhibitors in people with type 2 diabetes and no or early-stage CKD. This could guide treatment decisions in clinical practice worldwide and could target treatment more effectively than the ≥3 mg/mmol albuminuria threshold recommended by current international guidelines.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Jansz TT, Young KG, Hopkins R, et al. Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection. Diabetologia. 2025. PMID: 41206830. doi:10.1007/s00125-025-06577-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。